Tomonori Morimoto

Tomonori Morimoto

Auto-generated profile, based on publicly available information

Tomonori Morimoto

Graduate School of Medicine, Kyoto University 1 Kyoto

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YAYuki Aisu
Yuki Aisu
NONobu OSHIMA
Nobu OSHIMA
FHFuminori Hyodo
Fuminori Hyodo
AEAbdelazim Elsayed Elhelaly
Abdelazim Elsayed Elhelaly
AMAkihiko Masuo
Akihiko Masuo
KOKazutaka Obama
Kazutaka Obama
Pyruvate is situated at the intersection of oxidative phosphorylation (OXPHOS) and glycolysis, which are the primary energy-producing pathways in cells. Cancer therapies targeting these pathways have been previously documented, indicating that inhibiting one pathway may lead to functional compensation by the other, resulting in an insufficient antitumor effect. Thus, effective cancer treatment necessitates concurrent and comprehensive suppression of both. However, whether a metabolic switch between the metabolic pathways occurs in colorectal and gastric cancer cells and whether blocking it by inhibiting both pathways has an antitumor effect remain to be determined. In the present study, we used two small molecules, namely OXPHOS and glycolysis inhibitors, to target pyruvate metabolic pathways as a cancer treatment in these cancer cells. OXPHOS and glycolysis inhibition each augmented the other metabolic pathway in vitro and in vivo. OXPHOS inhibition alone enhanced glycolysis and showed antitumor effects on colorectal and gastric cancer cells in vitro and in vivo. Moreover, glycolysis inhibition in addition to OXPHOS inhibition blocked the metabolic switch from OXPHOS to glycolysis, causing an energy depletion and deterioration of the tumor microenvironment that synergistically enhanced the antitumor effect of OXPHOS inhibitors. In addition, using hyperpolarized 13C-magnetic resonance spectroscopic imaging (HP-MRSI), which enables real-time and in vivo monitoring of molecules containing 13C, we visualized how the inhibitors shifted the flux of pyruvate and how this dual inhibition in colorectal and gastric cancer mouse models altered the two pathways. Integrating dual inhibition of OXPHOS and glycolysis with HP-MRSI, this therapeutic model shows promise as a future "cancer theranostics" treatment option.

10 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
HMHiroyuki Matsubara
Hiroyuki Matsubara
HMHiroyuki Miyoshi
Hiroyuki Miyoshi
Fumihiko KakizakiFumihiko Kakizaki
Fumihiko Kakizaki
TMTomonori Morimoto
Tomonori Morimoto
KKKenji Kawada
Kenji Kawada
Makoto Mark TaketoMakoto Mark Taketo
Makoto Mark Taketo
Recent advances in combinatorial chemistry led to the discovery of inhibitors targeting the KRAS G12C-mutant protein. However, efficacy of its monotherapy on colorectal cancer is limited. Thus, effective combination drugs should be explored for applicable patients with colorectal cancer to fully benefit from the KRAS G12C inhibitor treatment. Here we used a patient-derived colorectal cancer stem cell (PD–CRC-SC) spheroid culture and showed that three-drug combination of inhibitors against KRAS G12C, EGFR, and FGFR synergistically suppressed the growth of colorectal cancer cells carrying the KRAS G12C mutation. Likewise, a combination of KRAS G12C and SHP2 inhibitors was also effective. Importantly, activation of the PI3K/AKT pathway in heregulin-responsive colorectal cancer cells canceled out the effect of KRAS G12C inhibition, which was largely overcome by PI3K inhibitors. These results reveal that evaluating efficacy of combination therapies with PD–CRC-SC spheroids can be a promising strategy to find the best regimen for patients with colorectal cancer.

20 May 2023 in Cancer Science
Verified
Journal Article
Open access
TMTomonori Morimoto
Tomonori Morimoto
YTYukitoshi Takemura
Yukitoshi Takemura
TMTakemitsu Miura
Takemitsu Miura
TYTakehito Yamamoto
Takehito Yamamoto
Fumihiko KakizakiFumihiko Kakizaki
Fumihiko Kakizaki
HMHiroyuki Miyoshi
Hiroyuki Miyoshi
Experimental techniques for patient‐derived cancer stem‐cell organoids/spheroids can be powerful diagnostic tools for personalized chemotherapy. However, establishing their cultures from gastric cancer remains challenging due to low culture efficiency and cumbersome methods. To propagate gastric cancer cells as highly proliferative stem‐cell spheroids in vitro, we initially used a similar method to that for colorectal cancer stem cells, which, unfortunately, resulted in a low success rate (25%, 18 of 71 cases). We scrutinized the protocol and found that the unsuccessful cases were largely caused by the paucity of cancer stem cells in the sampled tissues as well as insufficient culture media. To overcome these obstacles, we extensively revised our sample collection protocol and culture conditions. We then investigated the following second cohort and, consequently, achieved a significantly higher success rate (88%, 29 of 33 cases). One of the key improvements included new sampling procedures for tumor tissues from wider and deeper areas of gastric cancer specimens, which allowed securing cancer stem cells more reproducibly. Additionally, we embedded tumor epithelial pieces separately in both Matrigel and collagen type‐I as their preference to the extracellular matrix was different depending on the tumors. We also added a low concentration of Wnt ligands to the culture, which helped the growth of occasional Wnt‐responsive gastric cancer stem‐cell spheroids without allowing proliferation of the normal gastric epithelial stem cells. This newly improved spheroid culture method may facilitate further studies, including personalized drug‐sensitivity tests prior to drug therapy.

31 October 2025 in Cancer Science
Verified
Journal Article
Open access
FKFumihiko Kakizaki
Fumihiko Kakizaki
HMHiroyuki Miyoshi
Hiroyuki Miyoshi
TYTakehito Yamamoto
Takehito Yamamoto
TMTomonori Morimoto
Tomonori Morimoto
HMHiroyuki Matsubara
Hiroyuki Matsubara
Makoto Mark TaketoMakoto Mark Taketo
Makoto Mark Taketo
Based on mRNA Expression Profiles of 57 Patient‐Derived Colorectal Cancer Stem‐Like Cell ( CRC ‐ SC ) Lines Compared With Normal Colonic Epithelial Stem‐Like Cells ( NCE ‐ SCs ), we Identified Five CRC Subtypes. The First Subtype of CRC ‐ SCs Showed Markedly Increased Expression of MUC12 , PIGR , PLA2G2A , SLC4A4 , and ZG16 , Which Were Barely Detectable in the Other Subtypes. Importantly, Their Expression Correlated With Favorable Outcomes in Both the Discovery Cohort and Independent Two Test Cohorts From Public Databases. The Remaining Four Subtypes Showed High Expression of DEFA6 , BST2 , MAGEA6 , or IGF2 Compared With NCE ‐ SCs . Although the Expression of Each Gene Individually Influenced Patient Outcomes, Additional Co‐Expressed Genes Within Each Subtype Were Also Associated With Prognosis. Furthermore, Integrating the Five Subtype‐Specific Signatures Produced a Practical Prognostic Indicator, Designated as the General Colorectal Cancer Signature ( GCS ), and Provided Individualized Predictive Signatures for Each Patient. The Clinical Significance of GCS Was Further Validated in a Novel Orthotopic Xenograft Mouse Model, Which Recapitulated Patient Outcomes: CRC ‐ SCs With Low GCS Scores Developed Distinct Liver and Lung Metastases, Whereas Those With High Scores Did Not. Apparent Associations Were Observed Between Activating RAS / RAF Mutations and BST2 Expression, and Between the Absence of SMAD4 Mutation and IGF2 Expression, but These Had no Significant Impact on Patient Survival, Suggesting That Driver Gene Mutations May Not Directly Influence GCS . Collectively, Our Findings Provide a Comprehensive Overview of Clinically Relevant Molecular Subtypes of CRC ‐ SCs , Representing the Current Landscape of CRC Molecular Expression Subtypes. They Also Enable Rapid, Low‐Cost Outcome Prediction and Suggest Potential Targets for Therapeutics Development.

15 June 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
SKShoichi Kitano
Shoichi Kitano
HMHiroyuki Miyoshi
Hiroyuki Miyoshi
TYTakehito Yamamoto
Takehito Yamamoto
HMHiroyuki Matsubara
Hiroyuki Matsubara
TMTomonori Morimoto
Tomonori Morimoto
Makoto Mark TaketoMakoto Mark Taketo
Makoto Mark Taketo
The benefits of fibroblast growth factor receptor (FGFR) inhibitor therapy in several malignancies are often limited by the emergence of drug resistance. Recent studies have uncovered its molecular mechanisms, particularly in urothelial cancer and cholangiocarcinoma, but not yet in colorectal cancer (CRC). Here, we investigated FGFR inhibitor resistance mechanisms using patient-derived CRC stem-cell (SC) spheroids. To obtain FGFR inhibitor-resistant CRC-SC spheroid lines, we performed long-term in vitro treatment with FDA-approved pan-FGFR inhibitors, erdafitinib and futibatinib. The paired drug-resistant and parental spheroid stem cells were subjected to RNA-sequencing for mutational and transcriptional profiling. We examined the involvement of differentially expressed genes in resistance mechanisms by functional tests and CRISPR-mediated gene disruption. We established 7 FGFR inhibitor-resistant CRC-SC lines from 4 parental lines that responded well to FGFR inhibitors. All resistant lines showed EGFR mRNA upregulation and PTPRO mRNA downregulation, correlating with reduced sensitivities to the pan-FGFR inhibitors, erdafitinib and futibatinib. EGF stimulation of these lines induced MAPK and PI3K-AKT pathway activation more potently than that of their parental lines. Additionally, PTPRO gene disruption in the parental lines conferred resistance to erdafitinib and futibatinib by upregulating EGFR. Importantly, the combination treatment of resistant lines with an EGFR inhibitor erlotinib effectively suppressed the MAPK and PI3K-AKT signaling. In conclusion, Enhanced EGFR signaling, partly driven by PTPRO downregulation, was a key mechanism of acquired resistance to FGFR inhibitors in RAS/RAF wild-type CRC. The combination treatment with FGFR and EGFR inhibitors can be a promising strategy to overcome this resistance.